UroGen Pharma (URGN) Profit After Tax (2017 - 2026)

UroGen Pharma (URGN) has reported Profit After Tax for 10 consecutive years, with -$23.6 million the latest figure, recorded in Q1 2026.

• Quarterly Profit After Tax rose 46.26% year-over-year to -$23.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$133.2 million (up 3.77% YoY) and the FY2025 annual result came in at -$153.5 million, down 21.01% from the prior year.
• Profit After Tax improved to -$23.6 million in Q1 2026 per URGN's latest filing, from -$26.4 million in the prior quarter.
• Over the last five years, Profit After Tax for URGN reached as high as -$21.9 million in Q3 2023 and fell as low as -$49.9 million in Q2 2025.
• A 5-year average of -$30.4 million and a median of -$28.4 million in 2022 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2025 — Profit After Tax tumbled 49.53% — and 2026, when it soared 46.26%.
• Year by year, Profit After Tax stood at -$28.8 million in 2022, then gained by 9.73% to -$26.0 million in 2023, then slumped by 44.19% to -$37.5 million in 2024, then increased by 29.71% to -$26.4 million in 2025, then rose by 10.55% to -$23.6 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$23.6 million, -$26.4 million, and -$33.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.